bioRxiv Science⌕ Search

Biology subjects

Di Gesu, R.

Publications and source records attributed to Di Gesu, R..

2 recordsLinked to original sources

A stimuli-responsive ex vivo model of osteoarthritis demonstrates TLR4-mediated cartilage degradation and a Rapamycin-induced fast matrix recovery

BackgroundIn osteoarthritis (OA) TLR4 signaling leads to downstream activation of the phosphoinositide 3-kinases/ protein kinase B/ mammalian target of Rapamycin (PIK3/AKT/mTOR) pathway, a known modulator of autophagic mechanisms in chondrocytes. This paper focuses on creating a realistic ex vivo OA model that mimics elements of the pathophysiology of OA, allowing for further hypotheses-based investigations, and for use as a bench test for new therapeutic targets. ObjectiveTo study the downstream inflammatory and matrix changes in cartilage due to TLR4 signaling and the recovery achieved by a commonly used immunosuppressive drug, Rapamycin. MethodsIn an ex vivo 3D model based on healthy porcine cartilage explants, we mimicked the OA environment by LPS stimulation activating TLR4 signaling. Furthermore, we inhibited mTOR signaling via Rapamycin, which is accepted to attenuate the cartilage response to LPS-TLR4 activation. Histology and immunohistochemistry were used to evaluate the structural and biomolecular modifications driven by LPS and Rapamycin. ResultsThe explant model captured key features of OA, such as extracellular matrix degeneration and altered autophagy. The OA-like changes in the model were driven by TLR4 activation and mTOR signaling, well-known OA-related molecular pathways, and reversed by Rapamycin. ConclusionWe demonstrate that our explant model is responsive to LPS stimulation, leading to activation of OA-related biomolecular pathways, closely mimicking the native physiological processes. This evidence supports the potential of our model to act as a platform for OA studies, in particular related to the gut-joint axis in age-related OA, and for the screening of new disease-modifying molecules.

bioengineering↗

Engineered collagen-coated scaffolds for tendon regeneration: a multifunctional drug delivery approach

Tendon injuries rank among the most common musculoskeletal disorders, with their incidence rising steadily due to increased sports participation and an aging population. Current surgical treatments often fall short of clinical expectations due to poor biocompatibility, suboptimal mechanical properties, and frequent post-surgical fibrosis. Tissue engineering, however, offers promising alternatives by using biocompatible scaffolds that mimic the native tendon structure. This study aimed to develop an advanced tendon-like bundle replicating the microarchitecture and mechanical strength of native tendons. The scaffold was constructed from aligned electrospun poly-lactic acid (PLA) microfibers and designed to function as a drug delivery system for Rolipram, an antifibrotic agent. To improve cell-scaffold interactions, the scaffolds were coated with type-I collagen, a primary component of the tendon extracellular matrix (ECM). Morphological analyses confirmed the successful fabrication of smooth, well-aligned, bead-free fibers with controlled diameters, closely resembling the natural orientation and dimensions of tendon collagen fibers. Drug release was monitored for both uncoated and collagen-coated electrospun mats, with no burst release observed. Histological analysis demonstrated effective cellular infiltration by human tenocytes, with cells distributed throughout the scaffold after 14 days in culture. These results underscore the potential of tendon-like scaffolds as a promising platform for tendon repair, setting the stage for further optimization.

bioengineering↗